The Guidelines Adherence with the Polypill Study - GAP
GAP is a randomised controlled trial of fixed dose combination medication (Polypill) versus usual care for improved adherence to indicated pharmacotherapy among individuals at high risk of a cardiovascular event.
Aims
To assess whether provision of a polypill (containing low dose aspirin, a statin and two blood pressure lowering medicines) compared to usual cardiovascular medications improves adherence to indicated therapies and clinical outcomes among high-risk patients. Secondary aims are to measure prescription of combination therapy, barriers to adherence, quality of life, safety, cardiovascular events, prescriber acceptability, and healthcare resource consumption.
Methods
The study is a prospective, open, randomised controlled clinical trial of a polypill-based strategy compared to usual care among approximately 1000 individuals at high risk of cardiovascular events, augmented by a cost-effectiveness analysis and a formal process evaluation. The study will be conducted within general medical practices in Austalia, where participants will be followed up for an average of 18 months.
Institute Investigators
- Anushka Patel (Chief Investigator)
- Patrick Groenestein
- Stephen Jan
- Bruce Neal
Collaboration
- Department of Epidemiology and Preventative Medicine, Monash University, Victoria
Funding Agencies
This study is funded by a National Health and Medical Research Council (NHMRC) Project Grant , with additional funding provided through a Program Grant awarded by the NHMRC to researchers at The George Institute For International Health.